Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of “Moderate Buy” by Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned an average recommendation of “Moderate Buy” from the twenty-one ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $34.95.

NTLA has been the subject of several recent analyst reports. The Goldman Sachs Group restated a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Citigroup dropped their price objective on Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating for the company in a research report on Friday, May 9th. Guggenheim dropped their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, May 12th. Wolfe Research upgraded Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 price objective for the company in a research report on Monday, April 21st. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, May 29th.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in shares of Intellia Therapeutics during the fourth quarter worth approximately $25,000. Sterling Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after purchasing an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new position in shares of Intellia Therapeutics in the 4th quarter worth $40,000. Resona Asset Management Co. Ltd. bought a new position in shares of Intellia Therapeutics in the 4th quarter worth $43,000. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Up 6.7%

NTLA stock opened at $8.09 on Wednesday. The business has a 50 day moving average price of $7.93 and a two-hundred day moving average price of $10.01. The company has a market cap of $837.99 million, a price-to-earnings ratio of -1.49 and a beta of 2.14. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the prior year, the firm posted ($1.12) earnings per share. The business’s revenue was down 42.6% compared to the same quarter last year. On average, equities research analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.